Norepinephrine Infusion Combined With Goal-directed Fluid Therapy in Patients Undergoing Kidney Transplantations

NARecruitingINTERVENTIONAL
Enrollment

380

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

June 30, 2026

Conditions
Delayed Graft FunctionEnd Stage Renal DiseaseKidney Transplantation
Interventions
DRUG

Goal-Directed Fluid Therapy (GDFT)

Norepinephrine will be administered intravenously at a rate of 0.06 µg/kg/min, followed by the implementation of fluid therapy guided by SVV until reaching our target. In instances where SVV ≤ 13%, indicative of adequate effective circulating blood volume, the fluid infusion rate will be adjusted to 1 ml/kg/h. Conversely, if SVV \> 13%, denoting inadequate effective circulating blood volume, a rapid infusion of 1 ml/kg of crystalloid fluid will be administered over 2 minutes, with subsequent observation of fluid reactivity after a further 2-minute interval. This process is reiterated until SVV ≤ 13% is attained. Should SVV \> 13% recurs during surgery, the aforementioned intervention is repeated.

DRUG

Regular Fluid Therapy

Anesthesiologists will rely on their clinical expertise and intraoperative circulatory hemodynamic assessment to regulate fluid infusion rates and administer medications as necessary

Trial Locations (3)

110016

NOT_YET_RECRUITING

General Hospital of Northern Theatre Command, Shenyang

200127

RECRUITING

Renji Hospital, Shanghai

450052

NOT_YET_RECRUITING

the First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

RenJi Hospital

OTHER